We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Convalescent Plasma Compared to the Best Available Therapy for the Treatment of SARS-CoV-2 Pneumonia (COP-COVID-19)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04358783
Recruitment Status : Completed
First Posted : April 24, 2020
Last Update Posted : May 26, 2021
Information provided by (Responsible Party):
Dr. Adrian Camacho-Ortiz, Hospital Universitario Dr. Jose E. Gonzalez

Brief Summary:

In early December 2019, cases of pneumonia of unknown origin were identified in Wuhan, China. The causative virus was called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The World Health Organization (WHO) has recently declared coronavirus disease 2019 (COVID-19) a public health emergency of international concern.

According to the World Health Organization (WHO), the management of COVID-19 has focused primarily on infection prevention, detection and patient monitoring. However, there is no vaccine or specific treatment for SARS-CoV-2 due to the lack of evidence. Treatment options currently include broad-spectrum antiviral drugs but the efficacy and safety of these drugs is still unknown.

Convalescent plasma has previously been used to treat various outbreaks of other respiratory infections; however, it has not been shown to be effective in all the diseases studied. Therefore, clinical trials are required to demonstrate its safety and efficacy in patients with VIDOC-19.

The present work seeks to determine the mortality from any cause up to 14 days after plasma randomization of patients cured of COVID-19 compared to the Best Available Therapy in subjects with SARS-CoV-2 pneumonia. This is a 2:1 randomized, double-blind, single-center, phase 2, controlled clinical trial (plasma: best available therapy) for the treatment of SARS-CoV-2 pneumonia.

Condition or disease Intervention/treatment Phase
Coronavirus Infection Biological: Plasma Other: Best Available Therapy Phase 2

Detailed Description:
Randomized clinical trial comparing convalescent plasma to best available therapy (BAT) for the treatment of severely ill and critically ill patient with COVID-19: Patients will be electronically randomized 2:1 (plasma vs BAT) in a double blind fashion. Patients with SARS-CoV-2 PCR confirmed infection with pulmonary infiltrates and hypoxemia will be screened and invited to participate. Primary outcomes will be early all-cause mortality, and secondary outcomes will include all cause in hospital mortality, length of mechanical ventilation and hospital stay, time to PAO2 >200, progression of pulmonary infiltrates, antibody titers and time to negative PCR detection

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 31 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: RCT double blind comparative study
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: double blind
Primary Purpose: Treatment
Official Title: Phase II, Randomized, Double-blind, Controlled Clinical Trial Evaluating the Efficacy and Safety of Plasma From Patients Cured of COVID-19 Compared to the Best Available Therapy in Subjects With SARS-CoV-2 Pneumonia
Actual Study Start Date : April 27, 2020
Actual Primary Completion Date : May 1, 2021
Actual Study Completion Date : May 1, 2021

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Plasma
Convalescent plasma from cured COVID-19 patients y Supportive management depending on individual needs
Biological: Plasma
The plasma unit will be fractionated in 200 mL aliquots for storage at -80°C until use. After thawing, it shall be administered in a single 200 mL dose to subjects who are randomized to that arm.

Experimental: Best Available Therapy
Will receive supportive management depending on individual needs including.
Other: Best Available Therapy
It shall include, but not be limited to, oxygen therapy by means of a nasal cannula; high-flow nasal cannula; invasive or non-invasive mechanical ventilation; intravenous hydration; antibiotic therapy; thrombus prophylaxis; pain and fever management.

Primary Outcome Measures :
  1. Early all-cause mortality [ Time Frame: 14 days ]
    any cause mortality during the first 14 days of treatment

Secondary Outcome Measures :
  1. Time in days for SARS-CoV-2 RT-PCR negatives [ Time Frame: 90 days ]
    (48-hour sampling interval from day 3 of hospitalization to two consecutive negatives).

  2. The serum anti-SARS-CoV-2 antibody titres [ Time Frame: 90 days ]
    In subjects of both arms at day 0, 3, 7, 14 and 90.

  3. Detection of serum antibodies [ Time Frame: days 0, 3, 7, 14 and 90. ]
    Comparison of anti-SARS-CoV-2 antibody titers

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Men or women ≥18 years. If you are a woman of childbearing age, you must agree to practice abstinence or to use an effective method of contraception during the study period.
  2. Vascular access suitable for administration of hemocomponents.
  3. SARS-CoV-2 positive RT-PCR.
  4. Negative pregnancy test in case of a woman of reproductive age
  5. Signing of evidentiary document of informed consent.
  6. Hospital admission for SARS-CoV-2 pneumonia with supplemental oxygen requirements.
  7. Subjects who access the storage of biological samples for future examination.

Exclusion Criteria:

  1. Respiratory rate >30 RPM, SO2 <93%, PaO2/FiO2 <200 despite intervention with oxygen therapy after 60 minutes of hospitalization.
  2. New alteration of the state of alert that does not revert after interventions 60 minutes after admission to hospital.
  3. PAM ≤ 65mmHg despite initial resuscitation on arrival at the centre.
  4. Pregnant or breastfeeding patients.
  5. Patients that the investigators consider inappropriate to participate in the clinical trial
  6. Contraindication to transfusion or history of previous severe reaction to blood products.
  7. Have received any blood products in the last 120 days.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04358783

Layout table for location information
Hospital Universitario José E. Gonzalez
Monterrey, Nuevo Leon, Mexico, 64460
Sponsors and Collaborators
Hospital Universitario Dr. Jose E. Gonzalez
Layout table for investigator information
Principal Investigator: Adrian Camacho-Ortiz, MD Hospital Universitario "Dr. Jose Eleuterio Gonzalez, UANL
Numbers SIN. Coronavirus Disease 2019 ( COVID-19 ) Situation Report-71. Vol 2019.; 2020.
Disease C. Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease ( COVID-19 ). CDC. 2020;2019:4-6.
Yang Y, Yang M, Shen C, Wang F, Yuan J. Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections ABSTRACT : medRxiv. 2020.
Guidance I. Clinical management of severe acute respiratory infection ( SARI ) when COVID-19 disease is suspected . World Heal Organ. 2020:1-21.
Brunk D. FDA OKs Emergency Use of Convalescent Plasma for Seriously Ill COVID-19 Patients. medscape. 2020:28-29. doi:10.1001/jama.2020.4783
NORMA Oficial Mexicana NOM-253-SSA1-2012, Para la disposición de sangre humana y sus componentes con fines terapéuticos. D Of. 2012;Tercera Se.

Layout table for additonal information
Responsible Party: Dr. Adrian Camacho-Ortiz, Head of the Infectious Disease Department, Hospital Universitario Dr. Jose E. Gonzalez
ClinicalTrials.gov Identifier: NCT04358783    
Other Study ID Numbers: IF20-00002
First Posted: April 24, 2020    Key Record Dates
Last Update Posted: May 26, 2021
Last Verified: May 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Dr. Adrian Camacho-Ortiz, Hospital Universitario Dr. Jose E. Gonzalez:
Plasma from patients cured
SARS-CoV-2 pneumonia
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronavirus Infections
Respiratory Tract Infections
Lung Diseases
Respiratory Tract Diseases
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Virus Diseases